Notizie e Video - ABBVIE INC. - Inglese

AbbVie to Present at the Leerink Partners Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill., March 4, 2025 NORTH CHICAGO, Ill. , March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025 . Management will participate in a fireside chat at 7:40 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An...

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity PR Newswire NORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill. and HØRSHOLM, Denmark , March 3, 2025...

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis PR Newswire NORTH CHICAGO, Ill., Feb. 28, 2025 The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA) 1 The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and...

AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference PR Newswire NORTH CHICAGO, Ill., Feb. 26, 2025 NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 . Management will participate in a fireside chat at 8:10 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An...

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors PR Newswire NORTH CHICAGO, Ill., Feb. 14, 2025 Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025 . He will succeed Richard A. Gonzalez,...

AbbVie Declares Quarterly Dividend PR Newswire NORTH CHICAGO, Ill., Feb. 13, 2025 NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May 15, 2025 , to stockholders of record at the close of business on April 15, 2025 . Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies PR Newswire NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass. , Feb. 12, 2025...

U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options PR Newswire NORTH CHICAGO, Ill., Feb. 7, 2025 EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public...

Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign PR Newswire IRVINE, Calif., Feb. 6, 2025 Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle ® and Share Their Personal Stories. Natrelle ® is the #1 Selected Breast Implant by Leading U.S. Physicians * Offering the Largest Range of Options For Every Curve, Every Shape, For Every BODY. IRVINE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:...

Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons PR Newswire IRVINE, Calif., Feb. 5, 2025 New video content featuring Dr. Caroline Glicksman and Dr. Melinda (Mindy) Haws available now on the LIMITLESS YouTube channel LIMITLESS Leaders' Summit to be held February 5-6, 2025 in Boston , spotlighting engaging speakers, breakout sessions IRVINE, Calif. , Feb. 5, 2025 /PRNewswire/ --...

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., Jan. 31, 2025 Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12 , a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $56.334 Billion , an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an...

Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans PR Newswire NORTH CHICAGO, Ill., Jan. 29, 2025 AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes NORTH CHICAGO, Ill. , Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions 1,2 , Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature...

AbbVie Completes Acquisition of Nimble Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan. 23, 2025 Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now...

AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology PR Newswire NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- AbbVie...

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical...

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical...

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials...

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md. , Jan. 13, 2025...

AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Jan. 9, 2025 NORTH CHICAGO, Ill. , Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 . Management will participate in a fireside chat at 10:15 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An...

CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics PR Newswire IRVINE, Calif., Jan. 7, 2025 Get Treated with CoolSculpting ® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment † IRVINE, Calif. , Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting ® Elite. The celebration is an opportunity for consumers interested in...